在接受积极监测的甲状腺癌患者中GLP-1受体激活剂的影响
Armando Patrizio1, Samantha K Newman1, R Michael Tuttle1
1Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Journal of the Endocrine Society
|December 11, 2025
概括
类似葡萄糖类-1受体激动剂 (GLP-1RAs) 在积极监测中没有影响低风险乳头甲状腺癌患者的瘤生长. 需要进一步的研究来确认GLP-1RA在甲状腺癌患者中使用的安全性.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 代谢疾病 代谢疾病
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是已确立的糖尿病和肥胖症的治疗方法.
- GLP-1RAs对非骨髓性甲状腺恶性瘤的影响尚不清楚.
研究的目的:
- 调查GLP-1RA暴露对在积极监测下患有低风险乳头甲状腺癌的患者的瘤动态的影响.
主要方法:
- 一项回顾性观察队列研究比较了18名暴露于GLP-1RA的乳头甲状腺癌患者和37名未暴露的对照患者.
- 瘤动力学被评估在平均随访时间为5.5年,显著的增长定义为直径变化≥3毫米或体积变化>72%.
主要成果:
- 在GLP-1RA暴露组 (10.5%显著增长) 和未暴露组 (2.6%显著增长) (P = .53) 之间没有观察到瘤生长动力学的显著差异.
- 暴露于GLP-1RA并没有改变一些确实增长的大小瘤的瘤体积增长率.
结论:
- 在接受积极监测的低风险乳头甲状腺癌患者中,GLP-1RA治疗似乎不会影响瘤生长动力学.
- 需要进行更长的随访时间的大型研究,以确认GLP-1RA在接受主动监测的甲状腺癌患者中使用的安全性.
相关概念视频
Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
Synthesis and Regulation of Thyroid Hormones
7.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505
GPCRs Regulate Adenylyl Cylase Activity
7.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.2K


